Attached files
file | filename |
---|---|
10-K - FORM 10-K - AVANIR PHARMACEUTICALS, INC. | a57994e10vk.htm |
EX-21.1 - EX-21.1 - AVANIR PHARMACEUTICALS, INC. | a57994exv21w1.htm |
EX-31.1 - EX-31.1 - AVANIR PHARMACEUTICALS, INC. | a57994exv31w1.htm |
EX-32.1 - EX-32.1 - AVANIR PHARMACEUTICALS, INC. | a57994exv32w1.htm |
EX-23.1 - EX-23.1 - AVANIR PHARMACEUTICALS, INC. | a57994exv23w1.htm |
EX-31.2 - EX-31.2 - AVANIR PHARMACEUTICALS, INC. | a57994exv31w2.htm |
EX-99.1 - EX-99.1 - AVANIR PHARMACEUTICALS, INC. | a57994exv99w1.htm |
EX-32.2 - EX-32.2 - AVANIR PHARMACEUTICALS, INC. | a57994exv32w2.htm |
EX-10.21 - EX-10.21 - AVANIR PHARMACEUTICALS, INC. | a57994exv10w21.htm |
EX-10.24 - EX-10.24 - AVANIR PHARMACEUTICALS, INC. | a57994exv10w24.htm |
EX-10.22 - EX-10.22 - AVANIR PHARMACEUTICALS, INC. | a57994exv10w22.htm |
Exhibit 10.37
December 31,
2008
Keith Katkin
c/o Avanir Pharmaceuticals
101 Enterprise, Suite 300
Aliso Viejo, CA 92656
c/o Avanir Pharmaceuticals
101 Enterprise, Suite 300
Aliso Viejo, CA 92656
Re: First Amendment to Offer of Employment
Dear Keith:
This
letter amends the terms of the Offer of Employment (the
Agreement) dated as of March 13,
2007, by and between Avanir Pharmaceuticals (Avanir) and you as set forth below. Capitalized
terms not defined herein shall have the meaning specified in the Agreement.
1. The last paragraph of the section entitled Benefits and Expenses is hereby deleted in its
entirety and the following is substituted therefor:
In addition, if the Company terminates your employment without Cause or you Resign for Good Reason
(each as defined in the Change of Control Agreement), then, subject to your entering into and not
revoking the Companys standard form of release of claims in favor of the Company, you will be
entitled to severance pay equal to one year of Base Salary, with such severance benefit to be paid
in one lump sum on the first payroll date that is thirty days following the date of termination.
Additionally, in the event of your termination without Cause or a resignation for Good Reason, the
vesting of all of your unvested stock option shares will be accelerated in full so as to vest as of
the date of termination, and you will have 90 days to exercise all those stock option shares that
have vested as of the date of termination and the vesting of all restricted stock awards shall
accelerate so that such awards are fully vested. Anything in this Agreement to the contrary
notwithstanding, if at the time of your separation from service, you are determined by the Company
to be a specified employee within the meaning of Section 409A(a)(2)(B)(i) of the Internal Revenue
Code of 1986, as amended (the Code), and if any payment that you become entitled to under this
Agreement would be considered deferred compensation subject to interest and additional tax imposed
pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i)
of the Code, then no such payment shall be payable prior to the date
that is the earlier of (1) six
months and one day after your separation from service, or (2) your death.
2. The severance payments hereunder relate only to a termination in the absence of a Change of
Control (as defined in the Change of Control
Agreement) and are not duplicative of the benefits available under the Change of Control Agreement.
3. Except as amended herein, the Agreement is hereby confirmed in all other respects and nothing
contained herein shall be deemed a waiver of any right or abrogation of any obligation otherwise
existing under the Agreement except to the extent specifically provided for herein.
Please indicate your acceptance of this amendment to the Agreement by signing the enclosed copy of
this letter and returning it to me.
AVANIR PHARMACEUTICALS |
||||
By: | /s/ David J. Mazzo | |||
Name: | David J. Mazzo, Ph.D. | |||
Title: | Chairman, Compensation Committee | |||
Accepted and agreed: |
||
/s/ Keith A. Katkin
|
2